To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Representative for Florida's 12th congressional district. Republican.
Last Updated: Feb 13, 2015
Length: 11 pages
114th Congress (2015–2017)
This bill was introduced on February 13, 2015, in a previous session of Congress, but it did not receive a vote.
Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).
21 Cosponsors (16 Republicans, 5 Democrats)
What legislators are saying
“Bilirakis Joins Bipartisan Colleagues With a Rare Disease Advocate Running Across America”
— Rep. Gus Bilirakis [R-FL12] (Sponsor) on Mar 18, 2015
“Bilirakis OPENs the Door to Accelerating Cures & Treatments”
— Rep. Gus Bilirakis [R-FL12] (Sponsor) on Feb 13, 2015
Nov 20, 2014
Earlier Version — Introduced
This activity took place on a related bill, H.R. 5750 (113th).
Feb 13, 2015
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
H.R. 971 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 971. This is the one from the 114th Congress.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2021). H.R. 971 — 114th Congress: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015. Retrieved from https://www.govtrack.us/congress/bills/114/hr971
“H.R. 971 — 114th Congress: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015.” www.GovTrack.us. 2015. October 27, 2021 <https://www.govtrack.us/congress/bills/114/hr971>
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015, H.R. 971, 114th Cong..
|title=H.R. 971 (114th)
|accessdate=October 27, 2021
|author=114th Congress (2015)
|date=February 13, 2015
|quote=Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.